MAIA SCIENTIFIC, a wholly-owned subsidiary of Harvard Bioscience, develops, manufactures and markets novel instrumentation and applications for high quality/high content screening. The MIAS-2 microscopy readers, having both brightfield and fluorescence parameters, and the eaZYX imaging software, utilsing the concept of 'scale space' object-oriented analysis algorithms, offer unprecedented sensitivity, speed and flexibility across the drug discovery and development value chain. The MIAS-2 and eaZYX platforms allow genomics, target validation, assay development, drug discovery and ADMET R&D programs to be conducted on the same platform.
In close collaboration with its partners, MAIA develops innovative platform technologies, including mechanisation and assay development. The company's assay expertise includes cells, tissues, beads, and small animal organisms. MAIA's software and hardware are applied to create a specialised, customer-oriented product, such as genome research using small model organisms, or pre-clinical and clinical dermatology research.